How Many CareDx, Inc (NASDAQ:CDNA)’s Analysts Are Bearish?

March 18, 2018 - By Hazel Jackson

 How Many CareDx, Inc (NASDAQ:CDNA)'s Analysts Are Bearish?
Investors sentiment increased to 1.88 in 2017 Q3. Its up 1.15, from 0.73 in 2017Q2. It is positive, as 5 investors sold CareDx, Inc shares while 3 reduced holdings. 8 funds opened positions while 7 raised stakes. 6.43 million shares or 0.83% more from 6.38 million shares in 2017Q2 were reported.
Trellus Mngmt Limited Co reported 0.14% of its portfolio in CareDx, Inc (NASDAQ:CDNA). Geode Management Limited Com has 43,139 shares. Tpg Group Incorporated Holdg (Sbs) holds 0.01% of its portfolio in CareDx, Inc (NASDAQ:CDNA) for 174,378 shares. Gagnon Advsrs Ltd Llc has invested 2.68% in CareDx, Inc (NASDAQ:CDNA). Wells Fargo & Com Mn holds 1,139 shares. Panagora Asset accumulated 0% or 41,985 shares. Paragon Assocs Paragon Assocs Ii Joint Venture holds 4.02% in CareDx, Inc (NASDAQ:CDNA) or 1.27 million shares. Teton Inc reported 0% stake. Royal Savings Bank Of Canada, a Ontario – Canada-based fund reported 7 shares. 138,550 were reported by Perkins Cap Inc. Spark Inv Mgmt Lc holds 89,600 shares or 0.02% of its portfolio. Next Century Growth Invsts Ltd Liability Company holds 497,260 shares. Gagnon Secs Limited Com holds 2.17 million shares or 2.87% of its portfolio. The New York-based Blackrock has invested 0% in CareDx, Inc (NASDAQ:CDNA). Thompson Davis Communications stated it has 203,692 shares or 1.33% of all its holdings.

CareDx, Inc (NASDAQ:CDNA) Ratings Coverage

Among 5 analysts covering CareDx (NASDAQ:CDNA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CareDx had 10 analyst reports since September 25, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, January 8 by Piper Jaffray. The company was upgraded on Wednesday, September 27 by Raymond James. The company was initiated on Friday, September 25 by Craig Hallum. The stock has “Buy” rating by H.C. Wainwright on Wednesday, January 31. Craig Hallum maintained CareDx, Inc (NASDAQ:CDNA) rating on Monday, October 9. Craig Hallum has “Buy” rating and $10.0 target. The firm has “Buy” rating given on Tuesday, June 14 by Mizuho. The rating was downgraded by Raymond James on Monday, September 28 to “Market Perform”. The firm earned “Buy” rating on Sunday, September 24 by Piper Jaffray. Below is a list of CareDx, Inc (NASDAQ:CDNA) latest ratings and price target changes.

31/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $12.0 Maintain
08/01/2018 Broker: Piper Jaffray Rating: Buy New Target: $10.0 Maintain
27/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $12 Initiates Coverage On
09/10/2017 Broker: Craig Hallum Rating: Buy New Target: $10.0 Maintain
27/09/2017 Broker: Raymond James Old Rating: Market Perform New Rating: Outperform Upgrade
24/09/2017 Broker: Piper Jaffray Rating: Buy New Target: $3.0 Maintain

It closed at $5.79 lastly. It is down 74.10% since March 18, 2017 and is downtrending. It has underperformed by 90.80% the S&P500.

CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company has market cap of $165.62 million. The firm operates through two divisions, CareDx and Olerup. It currently has negative earnings. The Company’s commercialized testing solution includes the AlloMap heart transplant molecular test , a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.